Physician profile
Darwin Ashbaker
NPI 1114286127
$5,427.81
in general payments reported to CMS, 2019-2025
25 companies · $30.42 in 2025
The $30.42 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $977 · 2020: $31.79 · 2021: $108 · 2022: $284 · 2023: $3,935 · 2024: $60.90 · 2025: $30.42.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $3,000 · Travel and Lodging: $550 · Food and Beverage: $477.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $3,000.00 |
| Travel and Lodging | $549.82 |
| Food and Beverage | $476.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,714.62 | 2023 | Ion, Da Vinci Surgical System |
| Veran Medical Technologies, INC. | $965.28 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $90.41 | 2021-2023 | Lynparza |
| Glaxosmithkline, LLC. | $75.04 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $62.75 | 2021-2025 | Keytruda |
| Amgen INC. | $52.38 | 2022-2023 | Lumakras |
| United Therapeutics Corporation | $34.40 | 2024 | Remodulin, Orenitram |
| Lilly USA, LLC | $32.02 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.81 | 2021 | |
| Novartis Pharmaceuticals Corporation | $30.32 | 2023 | |
| Ambu INC. | $29.34 | 2022 | |
| Coaptech, INC. | $26.50 | 2024 | Puma System |
| Takeda Pharmaceuticals U.S.A., INC. | $26.10 | 2022 | |
| Mirati Therapeutics, INC. | $25.99 | 2023 | Krazati |
| Ceribell, INC. | $24.83 | 2023 | Ceribell Rapid Response Eeg |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $23.87 | 2022 | |
| Immunogen, INC. | $23.87 | 2023 | Elahere |
| Exelixis INC. | $23.67 | 2022 | |
| Grifols USA, LLC | $23.04 | 2022 | |
| Genzyme Corporation | $22.57 | 2020 | |
| Allergan, INC. | $20.93 | 2019 | |
| Electromed, INC. | $20.17 | 2022 | |
| Gilead Sciences, INC. | $18.51 | 2022 | |
| Genentech USA, INC. | $18.44 | 2023 | Tecentriq, Alecensa, Rozlytrek |
| Regeneron Healthcare Solutions, INC. | $11.95 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darwin Ashbaker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.